|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prat J: Ovarian carcinomas: Five distinct
diseases with different origins, genetic alterations, and
clinicopathological features. Virchows Arch. 460:237–249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y, Kim S and Kim IM: Regulation of
metastasis by microRNAs in ovarian cancer. Front Oncol. 4:1432014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tung CS, Wong KK and Mok SC: Biomarker
discovery in ovarian cancer. Womens Health (Lond). 4:27–40. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vasudevan S: Posttranscriptional
upregulation by microRNAs. Wiley Interdiscip Rev RNA. 3:311–330.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seashols-Williams SJ, Budd W, Clark GC, Wu
Q, Daniel R, Dragoescu E and Zehner ZE: miR-9 acts as an oncomiR in
prostate cancer through multiple pathways that drive tumour
progression and metastasis. PLoS One. 11:e01596012016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sulaiman SA, Ab Mutalib NS and Jamal R:
miR-200c regulation of metastases in ovarian cancer: Potential role
in epithelial and mesenchymal transition. Front Pharmacol.
7:2712016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiao L, Zhou H, Li XP, Chen J, Fang C, Mao
CX, Cui JJ, Zhang W, Zhou HH, Yin JY and Liu ZQ: MicroRNA-138 acts
as a tumor suppressor in non small cell lung cancer via targeting
YAP1. Oncotarget. 7:40038–40046. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Das DK, Naidoo M, Ilboudo A, Park JY, Ali
T, Krampis K, Robinson BD, Osborne JR and Ogunwobi OO: miR-1207-3p
regulates the androgen receptor in prostate cancer via
FNDC1/fibronectin. Exp Cell Res. 348:190–200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gopalan V, Islam F, Pillai S, Tang JC,
Tong DK, Law S, Chan KW and Lam AK: Overexpression of microRNA-1288
in oesophageal squamous cell carcinoma. Exp Cell Res. 348:146–154.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J, Dou Y and Sheng M: Inhibition of
microRNA-383 has tumor suppressive effect in human epithelial
ovarian cancer through the action on caspase-2 gene. Biomed
Pharmacother. 83:1286–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiao J, Lin HY, Zhu YY, Zhu YP and Chen
LW: MiR-126 regulates proliferation and invasion in the bladder
cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt
signaling pathway. Onco Targets Ther. 9:5181–5193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu D, Niu X, Pan H, Zhou Y, Zhang Z, Qu P
and Zhou J: Tumor-suppressing effects of microRNA-429 in human
renal cell carcinoma via the downregulation of Sp1. Oncol Lett.
12:2906–2911. 2016.PubMed/NCBI
|
|
17
|
Zhou Y, Liu Y, Hu C and Jiang Y:
MicroRNA-16 inhibits the proliferation, migration and invasion of
glioma cells by targeting Sal-like protein 4. Int J Mol Med.
38:1768–1776. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pan Y, Jiao G, Wang C, Yang J and Yang W:
MicroRNA-421 inhibits breast cancer metastasis by targeting
metastasis associated 1. Biomed Pharmacother. 83:1398–1406. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu J, Wang JG, Zhang L, Yang HP, Wang L,
Ding D, Chen Q, Yang WL, Ren KH, Zhou D, et al: MicroRNA-320a
inhibits breast cancer metastasis by targeting metadherin.
Oncotarget. 7:38612–38625. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang B, Yang Z, Wang H, Cao Z, Zhao Y,
Gong C, Ma L, Wang X, Hu X and Chen S: MicroRNA-320a inhibits
proliferation and invasion of breast cancer cells by targeting
RAB11A. Am J Cancer Res. 5:2719–2729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Zeng J, Pan J, Geng X, Li L, Wu J,
Song P, Wang Y, Liu J and Wang L: MiR-320a inhibits gastric
carcinoma by targeting activity in the FoxM1-P27KIP1 axis.
Oncotarget. 7:29275–29286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao H, Dong T, Zhou H, Wang L, Huang A,
Feng B, Quan Y, Jin R, Zhang W, Sun J, et al: miR-320a suppresses
colorectal cancer progression by targeting Rac1. Carcinogenesis.
35:886–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo T, Feng Y, Liu Q, Yang X, Jiang T,
Chen Y and Zhang Q: MicroRNA-320a suppresses in GBM patients and
modulates glioma cell functions by targeting IGF-1R. Tumour Biol.
35:11269–11275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun JY, Xiao WZ, Wang F, Wang YQ, Zhu YH,
Wu YF, Miao ZL and Lin YC: MicroRNA-320 inhibits cell proliferation
in glioma by targeting E2F1. Mol Med Rep. 12:2355–2359. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shang C, Zhang H, Guo Y, Hong Y, Liu Y and
Xue Y: MiR-320a down-regulation mediates bladder carcinoma invasion
by targeting ITGB3. Mol Biol Rep. 41:2521–2527. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yiwei T, Hua H, Hui G, Mao M and Xiang L:
HOTAIR interacting with MAPK1 regulates ovarian cancer skov3 cell
proliferation, migration, and invasion. Med Sci Monit.
21:1856–1863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rahman MT, Nakayama K, Rahman M, Katagiri
H, Katagiri A, Ishibashi T, Ishikawa M, Sato E, Iida K, Nakayama N,
et al: KRAS and MAPK1 gene amplification in type II ovarian
carcinomas. Int J Mol Sci. 14:13748–13762. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J
and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player
enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miao J, Wu S, Peng Z, Tania M and Zhang C:
MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects.
Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang T, Zou P, Wang T, Xiang J, Cheng J,
Chen D and Zhou J: Down-regulation of miR-320 associated with
cancer progression and cell apoptosis via targeting Mcl-1 in
cervical cancer. Tumour Biol. 37:8931–8940. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lei T, Zhu Y, Jiang C, Wang Y, Fu J, Fan Z
and Qin H: MicroRNA-320 was downregulated in non-small cell lung
cancer and inhibited cell proliferation, migration and invasion by
targeting fatty acid synthase. Mol Med Rep. 14:1255–1262. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang H, Yu J, Wang L, Ding D, Zhang L, Chu
C, Chen Q, Xu Z, Zou Q and Liu X: miR-320a is an independent
prognostic biomarker for invasive breast cancer. Oncol Lett.
8:1043–1050. 2014.PubMed/NCBI
|
|
35
|
Wu H, Li W, Zhang M, Zhu S, Zhang D and
Wang X: Inhibitory roles of miR-320 in osteosarcoma via regulating
E2F1. J Cancer Res Ther. 12:68–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tadano T, Kakuta Y, Hamada S, Shimodaira
Y, Kuroha M, Kawakami Y, Kimura T, Shiga H, Endo K, Masamune A, et
al: MicroRNA-320 family is downregulated in colorectal adenoma and
affects tumor proliferation by targeting CDK6. World J Gastrointest
Oncol. 8:532–542. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lu Y, Wu D, Wang J, Li Y, Chai X and Kang
Q: miR-320a regulates cell proliferation and apoptosis in multiple
myeloma by targeting pre-B-cell leukemia transcription factor 3.
Biochem Biophys Res Commun. 473:1315–1320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun L, Liu B, Lin Z, Yao Y, Chen Y, Li Y,
Chen J, Yu D, Tang Z, Wang B, et al: MiR-320a acts as a prognostic
factor and Inhibits metastasis of salivary adenoid cystic carcinoma
by targeting ITGB3. Mol Cancer. 14:962015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qi X, Li J, Zhou C, Lv C and Tian M:
MicroRNA-320a inhibits cell proliferation, migration and invasion
by targeting BMI-1 in nasopharyngeal carcinoma. FEBS Lett.
588:3732–3738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang W, Zhao L, Wei X, Wang L, Liu S, Yang
Y, Wang F, Sun G, Zhang J, Ma Y, et al: MicroRNA-320a promotes 5-FU
resistance in human pancreatic cancer cells. Sci Rep. 6:276412016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu M, Ding K, Zhang G, Yin M, Yao G, Tian
H, Lian J, Liu L, Liang M, Zhu T and Sun F: MicroRNA-320a
sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by
targeting ARPP-19 and ERRγ. Sci Rep. 5:87352015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wan LY, Deng J, Xiang XJ, Zhang L, Yu F,
Chen J, Sun Z, Feng M and Xiong JP: miR-320 enhances the
sensitivity of human colon cancer cells to chemoradiotherapy in
vitro by targeting FOXM1. Biochem Biophys Res Commun. 457:125–132.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC
and Hong TM: miR-320 regulates tumor angiogenesis driven by
vascular endothelial cells in oral cancer by silencing neuropilin
1. Angiogenesis. 17:247–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Seger R and Krebs EG: The MAPK signaling
cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
|
|
45
|
Li XW, Tuergan M and Abulizi G: Expression
of MAPK1 in cervical cancer and effect of MAPK1 gene silencing on
epithelial-mesenchymal transition, invasion and metastasis. Asian
Pac J Trop Med. 8:937–943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tsubaki M, Takeda T, Ogawa N, Sakamoto K,
Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T and
Nishida S: Overexpression of survivin via activation of ERK1/2,
Akt, and NF-κB plays a central role in vincristine resistance in
multiple myeloma cells. Leuk Res. 39:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang K, Chen H, Zhang B, Sun J, Lu J,
Chen K and Yang H: Overexpression of Raf-1 and ERK1/2 in sacral
chordoma and association with tumor recurrence. Int J Clin Exp
Pathol. 8:608–614. 2015.PubMed/NCBI
|
|
48
|
You B, Yang YL, Xu Z, Dai Y, Liu S, Mao
JH, Tetsu O, Li H, Jablons DM and You L: Inhibition of ERK1/2
down-regulates the Hippo/YAP signaling pathway in human NSCLC
cells. Oncotarget. 6:4357–4368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fei B and Wu H: MiR-378 inhibits
progression of human gastric cancer MGC-803 cells by targeting
MAPK1 in vitro. Oncol Res. 20:557–564. 2012. View Article : Google Scholar : PubMed/NCBI
|
